Ipamorelin research: what thirty years of work actually established

The gist

Ipamorelin research is small enough to read end to end, which is unusual and clarifying. The founding study, in 1998, proved the one thing the molecule is genuinely good at: releasing growth hormone without raising the stress hormone cortisol ^[1]. A 1999 study in humans measured how fast it clears — a roughly two-hour half-life and a single growth-hormone pulse about 40 minutes after dosing ^[2]. A rat study showed it speeds bone growth ^[4]. The one real efficacy trial in people, for sluggish bowels after surgery, did not work ^[3].

The biggest single body of work, though, is not about benefits at all — it is about detection. Anti-doping chemists built a series of mass-spectrometry methods specifically to catch ipamorelin and its relatives in urine ^{[7][8][9][10]}. That is the lens this page leads with: ipamorelin is, above all, a substance the labs learned to see.

Selectivity: the one thing it does cleanly

Ipamorelin's defining property arrived with its first full description. In 1998, Raun and colleagues showed the pentapeptide (sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2) released growth hormone potently in rat pituitary cells, anaesthetised rats, and conscious swine, with a swine ED50 of 2.3 nmol/kg — modestly more potent than GHRP-6 at 3.9 nmol/kg ^[1]. The headline was what it did not do: even at doses more than 200 times its growth-hormone threshold, it did not raise ACTH or cortisol above the level seen with growth-hormone-releasing hormone itself ^[1].

That selectivity is the whole reason the compound exists. Older growth-hormone-releasing peptides like GHRP-6 and GHRP-2 also stir up cortisol and prolactin; ipamorelin was engineered to drop those off-target effects. Mechanistically it is a selective agonist of the ghrelin receptor (GHS-R1a) on pituitary somatotrophs — the cells that store and release growth hormone — triggering calcium-driven release through a pathway distinct from, and complementary to, growth-hormone-releasing hormone ^[1].

What is ipamorelin peptide

Ipamorelin peptide is a wholly synthetic chain of five amino acids (Aib-His-D-2-Nal-D-Phe-Lys-NH2), built by removing the central dipeptide from the older peptide GHRP-1 and stabilizing it with non-natural residues that resist enzymatic breakdown. It is not a hormone the body makes; it mimics the action of ghrelin at the ghrelin receptor. Its molecular formula is C38H49N9O5, molecular weight about 711.9 daltons. The 1998 characterization established it as the first highly selective growth hormone secretagogue — potent growth-hormone release without cortisol elevation ^[1].

The human data: a two-hour half-life and a single pulse

Human evidence is thin but precise where it exists. A 1999 population pharmacokinetic-pharmacodynamic study gave eight healthy men per dose level five 15-minute intravenous infusions spanning 4.21 to 140.45 nmol/kg ^[2]. The kinetics were linear and dose-proportional: a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg, and a steady-state volume of distribution of 0.22 L/kg ^[2]. The growth-hormone response was a single discrete pulse, peaking around 40 minutes (0.67 h) after dosing ^[2].

That profile — short half-life, sharp single pulse — is the pharmacological fact underlying both the detection windows that matter to anti-doping and the dosing patterns seen in research-use communities. It is detailed further on the half-life page.

The one efficacy trial — and why it ended the program

The only published Phase 2 randomized controlled trial of ipamorelin tested it for postoperative ileus, the temporary bowel-motility shutdown that can follow abdominal surgery (NCT00672074) ^[3]. One hundred fourteen adults undergoing bowel resection received 0.03 mg/kg intravenously twice daily for up to 7 days ^[3]. The trial missed its primary endpoint: median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, a difference that did not reach statistical significance (p=0.15) ^[3].

The safety picture in that short window was unremarkable — treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm versus 94.8% of placebo, with no ipamorelin-specific signal ^[3]. But efficacy was not demonstrated, and no further clinical development followed. The lack of approval reflects a failed efficacy program, not merely incomplete development.

Animal data: bone growth and the freshest finding

In adult female rats, subcutaneous ipamorelin at 18, 90, and 450 microg/day (divided three times daily for 15 days) dose-dependently raised the longitudinal bone-growth rate from 42 microm/day in vehicle controls to 44, 50, and 52 microm/day respectively — with no change in total IGF-1 or bone-turnover markers, suggesting a partly local, pulse-driven skeletal effect ^[4].

The most recent in-vivo study, from 2024, used a ferret model of chemotherapy side effects. Intraperitoneal ipamorelin at 1 to 3 mg/kg blunted cisplatin-induced body-weight loss by about 24% on the last day of the delayed phase (48 to 72 hours), but had no anti-nausea effect on either acute or delayed emesis — unlike a related compound, anamorelin, which cut acute emesis by 60% when given centrally ^[5]. This is the freshest and most defensible recent ipamorelin finding.

Detection: the molecule the doping labs catch

The largest single thread in ipamorelin's literature is analytical. In 2012, a nano-scale liquid-chromatography method coupled to a benchtop quadrupole-Orbitrap mass spectrometer screened 11 prohibited peptides including ipamorelin in human urine, with limits of detection of 2 to 10 pg/mL — one of the first validated high-resolution multi-analyte doping-control assays to cover it ^[7].

A high-throughput LC-MS/MS method with peptide derivatization detected ipamorelin alongside seven other growth-hormone-releasing peptides in equine and human urine, confirming all eight (or their metabolites) in rat urine after intravenous dosing ^[8]. An earlier validated method determined ipamorelin and seven GHRPs from human urine at 0.2 to 1 ng/mL, using a retrospective non-targeted full-scan approach that surfaced previously unknown metabolites ^[9]. Analysts also characterized GHRP metabolites in human urine after nasal dosing ^[10]. Together these establish ipamorelin as a WADA-prohibited substance (category S2) with robust, validated urinary detection.

Ipamorelin cjc-1295

The ipamorelin cjc-1295 combination pairs a ghrelin-receptor agonist (ipamorelin) with a growth-hormone-releasing-hormone analog (CJC-1295). The pharmacological logic is that the two raise growth hormone by distinct, complementary mechanisms — ipamorelin through the ghrelin receptor, CJC-1295 through the GHRH receptor — so co-administration could produce a larger or more sustained growth-hormone response than either alone ^[1]. That rationale rests on each agent's single-agent pharmacology. No controlled trial has tested the combination for any clinical outcome; the popular stack is supported by mechanism, not by combination trials.

What is cjc 1295 ipamorelin

Cjc 1295 ipamorelin refers to a research-use combination of two separate peptides: CJC-1295, a growth-hormone-releasing-hormone analog, and ipamorelin, a selective ghrelin-receptor agonist. They are not a single molecule and not a marketed drug. Each works through a different receptor to raise growth hormone, which is the stated reason for combining them ^[1]. A 2020 andrology review discusses where growth hormone secretagogues like these sit in modern practice and the gap between their marketing and any approved indication ^[11].

Does cjc-1295 ipamorelin work

For raising growth hormone acutely, each component has single-agent pharmacology supporting a growth-hormone response — ipamorelin produces a sharp growth-hormone pulse in humans ^[2], and the combination's rationale is that the two mechanisms add together ^[1]. But "work" for body composition, recovery, or anti-aging outcomes has not been demonstrated in any controlled trial of the combination. A 2020 review frames growth hormone secretagogues as compounds whose marketed use outruns their evidence ^[11], and recent sports-medicine reviews classify ipamorelin as investigational with no reproducible human outcome data ^[16][17].

Ipamorelin vs sermorelin

Ipamorelin and sermorelin reach the same destination by different doors. Ipamorelin is a growth-hormone-releasing peptide (a GHRP) that acts on the ghrelin receptor ^[1]. Sermorelin is a growth-hormone-releasing hormone analog that acts on the separate GHRH receptor; a clinical review describes it as an approach to restoring growth-hormone secretion in adult-onset growth-hormone insufficiency ^[12]. The practical difference: ipamorelin mimics ghrelin and carries that receptor's appetite signal, while sermorelin mimics the body's own growth-hormone-releasing hormone. Neither is an approved ipamorelin product, and the two are routinely confused in marketing.

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is another GHRP-versus-GHRH-analog contrast. Ipamorelin acts on the ghrelin receptor ^[1]; tesamorelin is a stabilized growth-hormone-releasing-hormone analog acting on the GHRH receptor. The clinically meaningful distinction is regulatory: tesamorelin has an approved human indication in its labeled use, whereas ipamorelin has none and failed its only Phase 2 trial ^[3]. Within the broader secretagogue landscape, GHRH analogs (sermorelin, tesamorelin) and GHRPs (ipamorelin) are complementary classes often discussed — and sometimes combined — together ^[12].

How the recent reviews read it

The 2024-2026 literature is consistent and cautious. A 2026 structured narrative review of injectable peptides in sports medicine classified ipamorelin as an investigational growth-hormone-axis secretagogue with no reproducible human evidence for musculoskeletal outcomes, recommending use be confined to rigorous research protocols ^[16]. A 2026 review of approved and unapproved peptide therapies for musculoskeletal injury reached the same place: investigational, with preclinical signals but an absence of rigorous human trials and a real potential for harm ^[17]. A broader 2026 review of therapeutic peptides in metabolic and endocrine conditions placed the secretagogue class among promising-but-unproven agents needing further human study before safe use ^[18].